UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody

Journal of pharmacokinetics and pharmacodynamics, 2021-08, Vol.48 (4), p.563-580

2021

Volltextzugriff (PDF)

Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation

Pharmaceutics, 2019-04, Vol.11 (4), p.179

2019

Volltextzugriff (PDF)

Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-03, Vol.25 (2), p.343-348

2019

Volltextzugriff (PDF)

External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data

Research and practice in thrombosis and haemostasis, 2021-10, Vol.5 (7), p.e12599-n/a, Article e12599

2021

Volltextzugriff (PDF)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis

Pharmaceutics, 2017-10, Vol.9 (4), p.47

2017

Volltextzugriff (PDF)

Predicting Individual Changes in Terminal Half‐Life After Switching to Extended Half‐Life Concentrates in Patients With Severe Hemophilia

HemaSphere, 2022-04, Vol.6 (4), p.e694-n/a

2022

Volltextzugriff (PDF)

A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates

Journal of thrombosis and haemostasis, 2022-09, Vol.20 (9), p.2012-2021

2022

Volltextzugriff (PDF)

Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-07, Vol.30 (4), p.988-997

2024

Volltextzugriff (PDF)

Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-07, Vol.30 (4), p.925-932

2024

Volltextzugriff (PDF)

Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.358-365

2021

Volltextzugriff (PDF)

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Blood, 2020-11, Vol.136 (Supplement 1), p.21-22

2020

Volltextzugriff (PDF)

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Blood, 2020-11, Vol.136 (Supplement 1), p.22-23

2020

Volltextzugriff (PDF)

Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-05, Vol.26 (3), p.384-400

2020

Volltextzugriff (PDF)

Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization

Journal of pharmacokinetics and pharmacodynamics, 2019-10, Vol.46 (5), p.411-426

2019

Volltextzugriff (PDF)

Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models

British journal of clinical pharmacology, 2024-09, Vol.90 (9), p.2200-2214

2024

Volltextzugriff (PDF)

Pediatric Dose Selection for Therapeutic Proteins

Journal of clinical pharmacology, 2021-06, Vol.61 (S1), p.S193-S206

2021

Volltextzugriff (PDF)

Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database

Journal of thrombosis and haemostasis, 2021-08, Vol.19 (8), p.1896-1906

2021

Volltextzugriff (PDF)

A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients

Thrombosis research, 2019-12, Vol.184, p.31-37

2019

Volltextzugriff (PDF)

Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?

Journal of thrombosis and haemostasis, 2019-07, Vol.17 (7), p.1085-1096

2019

Volltextzugriff (PDF)

Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-03, Vol.30 (2), p.345-354

2024

Volltextzugriff (PDF)

Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.626-633

2021

Volltextzugriff (PDF)

Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-07, Vol.28 (4), p.542-547

2022

Volltextzugriff (PDF)

Evaluation and Calibration of In Silico Models of Thrombin Generation Using Experimental Data from Healthy and Haemophilic Subjects

Bulletin of mathematical biology, 2018-08, Vol.80 (8), p.1989-2025

2018

Volltextzugriff (PDF)

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

Clinical pharmacokinetics, 2020-02, Vol.59 (2), p.245-256

2020

Volltextzugriff (PDF)

Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-03, Vol.26 (2), p.282-289

2020

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody

Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation

Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients

External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis

Predicting Individual Changes in Terminal Half‐Life After Switching to Extended Half‐Life Concentrates in Patients With Severe Hemophilia

A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates

Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform

Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients

Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project

Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization

Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models

Pediatric Dose Selection for Therapeutic Proteins

Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database

A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients

Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?

Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A

Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis

Evaluation and Calibration of In Silico Models of Thrombin Generation Using Experimental Data from Healthy and Haemophilic Subjects

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates

Suchergebnisse filtern